NCT01738893View on ClinicalTrials.gov

Bioequivalence Study of 300 mg Gabapentin

PHASE1CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

January 14, 2011

Primary Completion Date

January 22, 2011

Study Completion Date

January 22, 2011

Conditions

Epilepsy

Interventions

DRUG

Gabapentin 300 mg

Test product

DRUG

Gabapentin 300 mg

Reference product

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01738893 - Bioequivalence Study of 300 mg Gabapentin | Biotech Hunter | Biotech Hunter